Rakowiczszulczynska E, Roszak A, Mackiewicz A, Markowska J, McIntosh D, Karczewska A, Godlewski D, Snyder W, Leary D, Smith M
UNIV NEBRASKA,EPPLEY CANC CTR,DEPT OBSTET & GYNECOL,OMAHA,NE. UNIV NEBRASKA,EPPLEY CANC CTR,DEPT BIOCHEM & MOL BIOL,OMAHA,NE. UNIV NEBRASKA,EPPLEY CANC CTR,EPPLEY CANC INST,OMAHA,NE. UNIV POSNAN,GREAT POLAND CANC CTR,SCH MED SCI,DEPT CANC IMMUNOL,POZNAN,POLAND. K MARCINKOWSKI UNIV,SCH MED,DEPT ONCOL,POZNAN,POLAND.
Int J Oncol. 1996 Oct;9(4):693-9. doi: 10.3892/ijo.9.4.693.
Cancer antigens RAK-p120, p42, and p25, which exhibit biological, immunological and molecular similarity to the proteins expressed by Human Immunodeficiency Virus 1 (HIV-1), were found in 47 of 47 tested cases of serous adenocarcinoma of the ovary, and 45 of 45 tested cases of squamous carcinoma of the cervix. Normal ovary and cervix did not express antigens RAK. High molecular weight protein (RAK-p160) was detected in the blood of over 61% of ovarian and 72% of cervical cancer patients, and in 14.3% of healthy women with family history of breast and/or gynecological cancer. Antigens RAK might represent new diagnostic markers.
癌症抗原RAK-p120、p42和p25，它们在生物学、免疫学和分子层面与人类免疫缺陷病毒1（HIV-1）所表达的蛋白质相似，在47例接受检测的卵巢浆液性腺癌病例中均被发现，在45例接受检测的宫颈鳞状癌病例中也均被发现。正常卵巢和宫颈不表达抗原RAK。在超过61%的卵巢癌患者和72%的宫颈癌患者血液中检测到高分子量蛋白质（RAK-p160），在有乳腺癌和/或妇科癌症家族史的健康女性中，这一比例为14.3%。抗原RAK可能代表新的诊断标志物。
